Health Care·Pharmaceuticals·$119.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.56 | N/A | +19.15% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.56 | N/A | +19.15% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management expressed confidence in their product pipeline and market position. They noted the importance of maintaining momentum in their core areas.
Management highlighted strong performance in key therapeutic areas.
They emphasized ongoing commitment to innovation and pipeline development.
This earnings report indicates that Bristol Myers Squibb is performing well, particularly in terms of EPS, which exceeded expectations. The stock reacted positively, rising by 2.81%, likely due to the strong EPS performance and management's optimistic tone regarding their product pipeline. However, the lack of revenue data and guidance may leave some investors cautious about future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
CANADIAN NATL RY CO
Jul 20, 2009